PRTA - Prothena Corporation plc
| Previous Close | 7.28 |
| Open | 7.23 |
| Bid | 6.85 x 900 |
| Ask | 7.10 x 900 |
| Day's Range | 6.84 - 7.28 |
| 52 Week Range | 6.84 - 15.91 |
| Volume | 184,068 |
| Avg. Volume | 217,738 |
| Market Cap | 274.888M |
| Beta (3Y Monthly) | 1.65 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.10 |
| Earnings Date | Nov 4, 2019 - Nov 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.60 |
- Zacks
Prothena (PRTA) Reports Q2 Loss, Lags Revenue Estimates
Prothena (PRTA) delivered earnings and revenue surprises of 28.57% and -22.33%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Prothena Reports Second Quarter 2019 Financial Results and Provides R&D Update
Net cash used in operating and investing activities was $12.2 million in the second quarter and $29.7 million for the first six months of 2019; quarter-end cash and restricted.
- GlobeNewswire
Prothena to Report Second Quarter 2019 Financial Results on August 6
Prothena Corporation plc (PRTA), a clinical-stage neuroscience company, will announce financial results for the second quarter and first six months of 2019 on August 6, 2019 after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on August 6. Prothena Corporation plc is a clinical-stage neuroscience company focused on the discovery and development of novel therapies with the potential to fundamentally change the course of devastating neurological disorders.
- Zacks
Will Prothena (PRTA) Report Negative Q2 Earnings? What You Should Know
Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Prothena Corporation plc (PRTA)
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]
- Simply Wall St.
Those Who Purchased Prothena (NASDAQ:PRTA) Shares Three Years Ago Have A 75% Loss To Show For It
As every investor would know, not every swing hits the sweet spot. But you have a problem if you face massive losses...
- GlobeNewswire
Prothena Announces Appointment of Paula K. Cobb to its Board of Directors
Prothena Corporation plc (PRTA), a clinical-stage neuroscience company, announced today the appointment of Paula Cobb to its Board of Directors. “As a biotechnology executive with wide-ranging global development, business strategy and commercial experience across a number of categories, Paula’s perspective will be invaluable as Prothena advances a pipeline of novel neuroscience programs targeting devastating diseases,” commented Lars Ekman, Prothena's Chairman.
- Zacks
Prothena (PRTA) Down 14.1% Since Last Earnings Report: Can It Rebound?
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GlobeNewswire
Prothena to Participate in the Jefferies Healthcare Conference
Prothena Corporation plc (PRTA), a clinical-stage neuroscience company, today announced that members of its senior management team will present and participate in the Jefferies Healthcare Conference on June 6th at 10:30 AM ET in New York, NY. A live webcast of the presentation can be accessed through the Investors section of the Company's website at www.prothena.com. Following the live presentation, a replay of the webcast will be available on the Company's website for at least 90 days following the presentation date.
- Insider Monkey
Here’s What Hedge Funds Think About Prothena Corporation plc (PRTA)
How do we determine whether Prothena Corporation plc (NASDAQ:PRTA) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows […]
- Zacks
Prothena's (PRTA) Q1 Earnings Beat Estimates, Revenues Miss
Prothena's (PRTA) Q1 loss was narrower than expected, while revenues missed expectations.
- Zacks
Prothena (PRTA) Reports Q1 Loss, Misses Revenue Estimates
Prothena (PRTA) delivered earnings and revenue surprises of 13.33% and -7.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press
Prothena: 1Q Earnings Snapshot
On a per-share basis, the Dublin-based company said it had a loss of 52 cents. The drug developer posted revenue of $186,000 in the period. Prothena shares have climbed slightly since the beginning of ...
- GlobeNewswire
Prothena Reports First Quarter 2019 Financial Results and Provides R&D Update
Net cash used in operating and investing activities was $17.6 million in the first quarter; quarter-end cash and restricted cash position of $414.2 million provides funding to.
- GlobeNewswire
Prothena to Report First Quarter 2019 Financial Results on May 7
Prothena Corporation plc (PRTA), a clinical-stage neuroscience company, will announce financial results for the first quarter of 2019 on May 7, 2019 after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on May 7. Prothena Corporation plc is a clinical-stage neuroscience company focused on the discovery and development of novel therapies with the potential to fundamentally change the course of progressive, life-threatening diseases.
- GlobeNewswire
Prothena Reports Results from the Phase 3 VITAL Amyloidosis Study of NEOD001 (birtamimab) in AL Amyloidosis
Prothena Corporation plc (PRTA), a clinical-stage neuroscience company, today reported final results from the Phase 3 VITAL Amyloidosis study of NEOD001 (birtamimab) in newly diagnosed, treatment naïve patients with AL Amyloidosis and cardiac dysfunction (N=260), which was discontinued in 2018.
- ACCESSWIRE
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Prothena Corporation plc and Encourages Investors who Purchased Shares in the March 2017 Secondary Offering to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 4, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prothena Corporation plc (''Prothena'' or ''the Company'') (NASDAQ: PRTA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors related to its secondary offering on March 8, 2017.
- ACCESSWIRE
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Prothena Corporation plc and Encourages Investors who Purchased Shares in the March 2017 Secondary Offering to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 26, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prothena Corporation plc (''Prothena'' or ''the Company'') (NASDAQ: PRTA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors related to its secondary offering on March 8, 2017.
- Zacks
Why Is Prothena (PRTA) Up 12.6% Since Last Earnings Report?
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GuruFocus.com
Prothena Corp PLC (PRTA) Files 10-K for the Fiscal Year Ended on December 31, 2018
Prothena Corp PLC (NASDAQ:PRTA) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018.
- ACCESSWIRE
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Prothena Corporation plc and Encourages Investors who Purchased Shares in the March 2017 Secondary Offering to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 15, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prothena Corporation plc (''Prothena'' or ''the Company'') (NASDAQ: PRTA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors related to its secondary offering on March 8, 2017.
- GlobeNewswire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Prothena Corporation plc and Encourages Investors who Purchased Shares in the March 2017 Secondary Offering to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prothena Corporation plc (“Prothena” or “the Company”) (NASDAQ: PRTA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors related to its secondary offering on March 8, 2017.
- Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Prothena Corporation plc and Encourages Investors who Purchased Shares in the March 2017 Secondary Offering to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prothena Corporation plc (“Prothena” or “the Company”) (NASDAQ: PRTA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether BrightView issued false and/or misleading statements and/or failed to disclose information pertinent to investors related to its secondary offering on March 8, 2017. On or about March 8, 2017, Prothena Corporation plc completed a secondary offering of 2,700,000 of its ordinary shares at a price of $57.50 per share.
- Simply Wall St.
Prothena Corporation plc (NASDAQ:PRTA): Will The Growth Last?
Prothena Corporation plc's (NASDAQ:PRTA) released its most recent earnings update in December 2018, which signalled company earnings became less negative compared to the previous year's level as a result ofRead More...
- GlobeNewswire
Prothena to Participate in Upcoming March Healthcare Conferences
DUBLIN, Ireland, March 05, 2019 -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, today announced that members of its senior management team.
